Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety of Fentanyl Sublingual Spray for Breakthrough Cancer Pain
NCT00538863Phase 3Completed
- Sponsor
- Insys Therapeutics
- Start
- Dec 2007
- Primary completion
- Oct 2010
- Modality
- Small Molecules
- Countries
- 3
01
Overview
A Phase 3 trial of fentanyl (transdermal patch + oral transmucosal lozenge) in breakthrough cancer pain (BTcP), sponsored by Insys Therapeutics. Started Dec 2007; status: completed.
02
Drugs
fentanyl (transdermal patch + oral transmucosal lozenge)
03
Conditions
breakthrough cancer pain (BTcP)
Beyond the preview
Go deeper on NCT00538863.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00538863.